BioCardia (BCDA) Reports Q3 Results; Targets Helix FDA Submission in Coming Months

BioCardia reported Q3 2026 financial results and said it aims to be able to submit its Helix delivery platform for FDA approval in the coming months. No financial figures are included in the release.Material DetailsContext by AI AnalystThis is an early-stage clinical and regulatory story, with mana…